American Association for Cancer Research
00085472can141913-sup-133894_1_supp_2635415_nb16qn.pdf (1.15 MB)

Supplementary Figures S1-S5 from Chemoradiotherapy-Induced Upregulation of PD-1 Antagonizes Immunity to HPV-Related Oropharyngeal Cancer

Download (1.15 MB)
journal contribution
posted on 2023-03-30, 23:05 authored by Falguni Parikh, Dorothée Duluc, Naoko Imai, Amelia Clark, Krzys Misiukiewicz, Marcello Bonomi, Vishal Gupta, Alexis Patsias, Michael Parides, Elizabeth G. Demicco, David Y. Zhang, Seunghee Kim-Schulze, Johnny Kao, Sacha Gnjatic, Sangkon Oh, Marshall R. Posner, Andrew G. Sikora

All supplementary Figures S1-S5. FIGURE S1. Gating scheme. FIGURE S2. Effect of chemoradiation on circulating immunocytes. FIGURE S3. Intracellular IFN-γ and TNF-α staining in CD8+ and CD4+ T cells. FIGURE S4. Effect of chemoradiotherapy on PD-1 expression on CD8+T cells. FIGURE S5. Baseline PD-1 expression is correlated with post-treatment PD-1 expression on CD4+ T cells.



While viral antigens in human papillomavirus (HPV)-related oropharyngeal cancer (HPVOPC) are attractive targets for immunotherapy, the effects of existing standard-of-care therapies on immune responses to HPV are poorly understood. We serially sampled blood from patients with stage III–IV oropharyngeal cancer undergoing concomitant chemoradiotherapy with or without induction chemotherapy. Circulating immunocytes including CD4+ and CD8+ T cells, regulatory T cells (Treg), and myeloid-derived suppressor cells (MDSC) were profiled by flow cytometry. Antigen-specific T-cell responses were measured in response to HPV16 E6 and E7 peptide pools. The role of PD-1 signaling in treatment-related immunosuppression was functionally defined by performing HPV-specific T-cell assays in the presence of blocking antibody. While HPV-specific T-cell responses were present in 13 of 18 patients before treatment, 10 of 13 patients lost these responses within 3 months after chemoradiotherapy. Chemoradiotherapy decreased circulating T cells and markedly elevated MDSCs. PD-1 expression on CD4+ T cells increased by nearly 2.5-fold after chemoradiotherapy, and ex vivo culture with PD-1–blocking antibody enhanced HPV-specific T-cell responses in 8 of 18 samples tested. Chemoradiotherapy suppresses circulating immune responses in patients with HPVOPC by unfavorably altering effector:suppressor immunocyte ratios and upregulating PD-1 expression on CD4+ T cells. These data strongly support testing of PD-1–blocking agents in combination with standard-of-care chemoradiotherapy for HPVOPC. Cancer Res; 74(24); 7205–16. ©2014 AACR.

Usage metrics

    Cancer Research



    Ref. manager